Video Library

Search the Video Library

Filter by Date

Displaying Results 16 - 30 of 59

Transcript More and more, when people are doing molecular testing on their tumor, they’re not just getting one test and if it’s negative doing another test — that’s called sequential testing, they’re doing lots of tests at the same time — that’s called multiplex testing. There are certain good

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.

Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.

Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation therapy.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the benefits and drawbacks of lung cancer screenings.

Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.